Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pediatric Transplants

Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients

Abstract

We studied the administration method during a transition period from continuous intravenous (i.v.) infusion to oral administration of cyclosporin A (CsA). Thirty-two pediatric hematopoietic stem cell transplant (HSCT) recipients, between the ages of 8 months and 15.6 years (median 7.1 years) participated in this study. The pharmacokinetic properties of CsA was evaluated during the transition period from i.v. to oral CsA. The daily oral dose of CsA was three times higher than the i.v. dose. Oral dosing began immediately after the continuous infusion was discontinued. Whole-blood CsA concentrations were measured by a monoclonal fluorescence polarization immunoassay (FPIA). The mean±s.d. value of bioavailability (F), maximum concentration (Cmax), half-life (t1/2) of CsA were 43.1±14.4%, 1135.3±340.6 ng/ml and 3.1±1.2 h, respectively. Mean clearance (CL)±s.d. was 480.9±103.7, 414.9±137.1 and 320±51.8 ml/h/kg in patients <20, 20–40 and >40 kg of body weight, respectively. The CsA CL of younger children was significantly greater than for older children (P=0.044). CsA trough levels were maintained within the therapeutic range throughout the transition period. Therefore, our findings suggest that the immediate administration of an oral formulation, after discontinuation of the continuous infusion, would be practical and effective for routine clinical use.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Atkinson K . Cyclosporin in bone marrow transplantation. Bone Marrow Transplant 1987; 1: 265–270.

    CAS  PubMed  Google Scholar 

  2. Storb R, Deeg HJ, Pepe M, Frederick A, Anasetti C, Beatty P et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729–1734.

    CAS  PubMed  Google Scholar 

  3. Yau JC, LeMaistre CF, Zagars GK, William LA, Meneghetti CM, Luke DR et al. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplant 1990; 5: 269–272.

    CAS  PubMed  Google Scholar 

  4. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225–1230.

    Article  CAS  PubMed  Google Scholar 

  5. Simpson D . Drug therapy for acute graft-versus-host disease prophylaxis. J Hematother Stem Cell Res 2000; 9: 317–325.

    Article  CAS  PubMed  Google Scholar 

  6. Arai S, Vogelsang GB . Management of graft-versus-host disease. Blood Rev 2000; 14: 190–204.

    Article  CAS  PubMed  Google Scholar 

  7. Locatelli F, Uderzo C, Dini G, Zecca M, Arcese W, Messina C et al. Graft-versus-host disease in children: the AIEOP-BMT group experience with cyclosporin A. Bone Marrow Transplant 1993; 12: 627–633.

    CAS  PubMed  Google Scholar 

  8. Peters C, Minkov M, Gadner H, Klingebiel T, Vossen J, Locatelli F et al. Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant 2000; 26: 405–411.

    Article  CAS  PubMed  Google Scholar 

  9. Shaw LM, Bowers L, Demers L, Freeman D, Moyer T, Sanghvi A et al. Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring. Clin Chem 1987; 33: 1269–1288.

    CAS  Google Scholar 

  10. Lindholm A, Henricsson S, Lind LM, Dahlqvist R . Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. Eur J Clin Pharmacol 1988; 34: 461–464.

    Article  CAS  PubMed  Google Scholar 

  11. Fahr A . Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24: 472–495.

    Article  CAS  PubMed  Google Scholar 

  12. Lindholm A . Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monitor 1991; 13: 465–477.

    Article  CAS  Google Scholar 

  13. Atkinson K, Biggs JC, Britton K, Short R, Mrongovius R, Concannon A et al. Oral administration of cyclosporin A for recipients of allogeneic marrow transplants: implications of clinical gut dysfunction. Br J Hematol 1984; 56: 223–231.

    Article  CAS  Google Scholar 

  14. Yee GC . Pharmacokinetic and pharmacodynamic studies of cyclosporine in bone marrow transplantation. Transplant Proc 1990; 22: 1327–1330.

    CAS  PubMed  Google Scholar 

  15. Schultz KR, Nevill TJ, Balshaw RF, Toze CL, Corr T, Currie CJ et al. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. Bone Marrow Transplant 2000; 26: 545–551.

    Article  CAS  PubMed  Google Scholar 

  16. Yee GC, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ . Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 1986; 40: 438–443.

    Article  CAS  PubMed  Google Scholar 

  17. Cooney GF, Habucky K, Hoppu K . Cyclosporin pharmacokinetics in pediatric transplant recipients. Clin Pharmacokinet 1997; 32: 481–495.

    Article  CAS  PubMed  Google Scholar 

  18. Burckart G, Starzl T, Williams L, Sanghvi A, Gartner C, Venkataramanan JR et al. Cyclosporine monitoring and pharmacokinetics in pediatric liver transplant patients. Transplant Proc 1985; 17: 1172–1175.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Burckart GJ, Venkataramanan R, Ptachcinski RJ, Ptachcinski RJ, Starzl TE, Gartner JC et al. Cyclosporine absorption following orthotopic liver transplantation. J Clin Pharmacol 1986; 26: 647–651.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Dunn SP, Cooney GF, Kulinsky A, Falkenstein K, Pierson A, Elder CA et al. Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients. Transplantation 1995; 60: 1438–1442.

    Article  CAS  PubMed  Google Scholar 

  21. Neiberger R, Weiss R, Gomez M, Greifer I, Tellis VA, Matas AJ . Elimination kinetics of cyclosporine following oral administration to children with renal transplants. Transplant Proc 1987; 19: 1525.

    CAS  PubMed  Google Scholar 

  22. Hoppu K, Koskimies O, Holmberg C, Hirvisalo EL . Pharmacokinetically determined cyclosporine dosage in young children. Pediatr Nephrol 1991; 5: 1–4.

    Article  CAS  PubMed  Google Scholar 

  23. Whitington PF, Emond JC, Whitington SH, Broelsch CE, Baker AL . Small bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med 1990; 322: 733–738.

    Article  CAS  PubMed  Google Scholar 

  24. Mochon M, Cooney G, Lum B, Caputo C, Dunn S, Goldsmith B et al. Pharmacokinetics of cyclosporine after renal transplant in children. J Clin Pharmacol 1996; 36: 580–586.

    Article  CAS  PubMed  Google Scholar 

  25. Cooney GF, Dunn SP, Kaiser B, Kulinsky AV, Mochon M, Heifets M . Oral cyclosporine pharmacokinetics in pediatric renal and liver transplant recipients. Transplant Proc 1994; 26: 2779–2780.

    CAS  PubMed  Google Scholar 

  26. Dunn S . Neoral use in the pediatric transplant recipient. Transplant Proc 2000; 32 (Suppl 3A): 20–26.

    Article  CAS  Google Scholar 

  27. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL . Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®) in organ transplantation. Drugs 2001; 61: 1957–2016.

    Article  CAS  PubMed  Google Scholar 

  28. Caudell KA, Adams J . Cyclosporine administration practices on bone marrow transplant units: a national survey. Oncol Nurs Forum 1990; 17: 563–568.

    CAS  PubMed  Google Scholar 

  29. Miller KB, Schenkein DP, Comenzo R, Erban JK, Fogaren T, Hirsch CA et al. Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 1994; 68: 15–20.

    Article  CAS  PubMed  Google Scholar 

  30. Witte T, Hoitsma A, Manoiu MM, Janssen J . Monitoring of cyclosporin during continuous intravenous administration. Bone Marrow Transplant 1986; 1: 147–150.

    PubMed  Google Scholar 

  31. Kagawa Y, Sawada J, Yamada S, Matsuda H, Kageyama S, Masuya M et al. Relationship between development of nephrotoxicity and blood concentration of cyclosporine A in bone marrow transplanted recipients who received the continuous intravenous infusion. Biol Pharm Bull 2003; 26: 1115–1119.

    Article  CAS  PubMed  Google Scholar 

  32. Lindholm A . Therapeutic monitoring of cyclosporin – an update. Eur J Clin Pharmacol 1991; 41: 273–283.

    Article  CAS  PubMed  Google Scholar 

  33. Morris RG, Ilett KF, Tett SE, Ray JE, Fullinfaw RO, Cooke R et al. Cyclosporin monitoring in Australasia: 2002 update of consensus guidelines. Ther Drug Monitor 2002; 24: 677–688.

    Article  CAS  Google Scholar 

  34. Kari T . A review of assay methods for cyclosporin. Clin Phatmacokinet 1992; 23: 173–190.

    Article  Google Scholar 

  35. Holt DW, Johnson A . Cyclosporin A: analytic methodology and factors affecting therapeutic drug monitoring. Ther Drug Monitor 1995; 17: 625–630.

    Article  CAS  Google Scholar 

  36. Nashan B, Bleck J, Wonigeit K, Vogt P, Christians U, Sewing KF et al. Effect of the application form of cyclosporine on blood levels: comparison of oral solution and capsules. Transplant Proc 1988; 20: 637–639.

    CAS  PubMed  Google Scholar 

  37. Hilbrands LB, Hoitsma AJ, van den Berg JWO, Koene RAP . Cyclosporin A blood levels during use of cyclosporin as oral solution or in capsules: comparison of pharmacokinetic parameters. Transplant Int 1991; 4: 125–127.

    CAS  Google Scholar 

  38. Eadon H, Rose M, O'Neill R, Leaver N, Yacoub M . A pharmacokinetic comparison of cyclosporin oral solution and cyclosporin capsules in heart and lung transplant recipients. Transpl Int 1995; 8: 35–40.

    Article  CAS  PubMed  Google Scholar 

  39. Papachristou F, Gakis D, Sotiriou I, Liatsis I, Takoudas D, Antoniadis A . Pharmacokinetic study of twice vs thrice daily dosing of Sandimmun Neoral in pediatric renal transplant patients. Transplant Proc 1998; 30: 1988–1990.

    Article  CAS  PubMed  Google Scholar 

  40. Portman RJ, Meier-Kriesche HU, Swinford R, Brannan P, Kahan BD . Reduced variability of Neoral pharmacokinetic studies in pediatric renal transplantation. Pediatr Nephrol 2000; 15: 2–6.

    Article  PubMed  Google Scholar 

  41. Blifeld C, Ettenger RB . Measurement of cyclosporine levels in samples obtained from peripheral sites and indwelling lines. NEJM 1987; 317: 509.

    CAS  PubMed  Google Scholar 

  42. Carreras E, Lozano M, Deulofeu R, Roman S, Granena A, Rozman C . Influence of different indwelling lines on the measurement of blood cyclosporin A levels. Bone Marrow Transplant 1988; 3: 637–639.

    CAS  PubMed  Google Scholar 

  43. Busca A, Miniero R, Vassallo E, Leone L, Oddenino O, Madon E . Monitoring of cyclosporine blood levels from central venous lines: a misleading assay? Ther Drug Monitor 1994; 16: 71–74.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H H Koo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choi, J., Lee, S., Chung, S. et al. Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 38, 29–35 (2006). https://doi.org/10.1038/sj.bmt.1705402

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705402

Keywords

This article is cited by

Search

Quick links